Eduardo Ferreira Borba
Eduardo Ferreira Borba publishes mostly in Rheumatology, Epidemiology and Pathology and Forensic Medicine, on topics such as Systemic Lupus Erythematosus Research, Rheumatoid Arthritis Research and Therapies and Systemic Sclerosis and Related Diseases.
- World rank
- #1,285,987 of 7,710,434 ranked researchers
- Rank in Brazil
- #9,228 of 253,246
- Works
- 351
- Citations
- 6.5k
- Citations per work
- 18.5
What does Eduardo Ferreira Borba research?
Eduardo Ferreira Borba's work is mostly in Medicine (49%), Immunology and Microbiology (7%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences17148.8%
- Medicine17148.8%
- Everything else15744.6%
- Life Sciences236.6%
- 1Rheumatology28% of their works
- 2Epidemiology7% of their works
- 3Pathology and Forensic Medicine7% of their works
- 4Immunology7% of their works
- 5Ophthalmology3% of their works
- 6Infectious Diseases3% of their works
Research topics
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Systemic Sclerosis and Related Diseases
- Atherosclerosis and Cardiovascular Diseases
- Inflammatory Myopathies and Dermatomyositis
- Drug-Induced Ocular Toxicity
- Cytomegalovirus and herpesvirus research
- Autoimmune and Inflammatory Disorders Research
Which keywords describe Eduardo Ferreira Borba's research?
The keywords of their largest research topics: Autoantibodies, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Cytokines, Inflammation, Treatment, Biological Therapy and Rheumatoid Arthritis.
- Juvenile Idiopathic Arthritis
- Infection
- Retinopathy
- Inflammatory Myopathies
- Immune Response
- Systemic Sclerosis
- Rheumatoid Arthritis
- Treatment
- Cytokines
- Antiphospholipid Syndrome
- Autoantibodies
- Systemic Lupus Erythematosus
- Inflammation
- Biological Therapy
- Fibrosis
- Atherosclerosis
- Dermatomyositis
- Chloroquine
- Cytomegalovirus
- Hemophagocytic Lymphohistiocytosis
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 20 words, with their numbers
- Autoantibodies2994 topics
- Antiphospholipid Syndrome1991 topic
- Systemic Lupus Erythematosus1991 topic
- Cytokines752 topics
- Inflammation752 topics
- Treatment592 topics
- Biological Therapy411 topic
- Rheumatoid Arthritis411 topic
- Fibrosis391 topic
- Systemic Sclerosis391 topic
- Atherosclerosis341 topic
- Immune Response341 topic
- Dermatomyositis201 topic
- Inflammatory Myopathies201 topic
- Chloroquine181 topic
- Retinopathy181 topic
- Cytomegalovirus151 topic
- Infection151 topic
- Hemophagocytic Lymphohistiocytosis141 topic
- Juvenile Idiopathic Arthritis141 topic
Where does Eduardo Ferreira Borba work?
Eduardo Ferreira Borba's main affiliation in the publication record is Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.
How many publications and citations does Eduardo Ferreira Borba have?
OpenAlex counts 351 works and 6,498 citations for Eduardo Ferreira Borba, an h-index of 45, ranking #1,285,987 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Eduardo Ferreira Borba. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.